1RCT2014
Beck DE, Sweeney WB, McCarter MD, Beart R · Int J Colorectal Dis (2014)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
12 peer-reviewed studies
What the evidence says
Most Ipamorelin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 1998–2024.
Based on 12 studies · 2 RCTs
Confidence
Low confidenceBy outcome
Only 1 study in the last 5 years
Beck DE, Sweeney WB, McCarter MD, Beart R · Int J Colorectal Dis (2014)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Gobburu JV, Agersø H, Jusko WJ, Ynddal L · Pharm Res (1999)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo.
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. · Eur J Endocrinol (1998)
In plain English: Ipamorelin dose-dependently increased LGR from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001).
Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. · Growth Horm IGF Res (1999)
In plain English: By a rational approach we were able to reduce the size of the lead compound ipamorelin and simultaneously to reduce hydrogen-bonding potential ... while retaining in vivo potency in swine.
Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J, Peschke B, Lundt BF, Thøgersen H, Johansen NL, Madsen K, Andersen PH. · J Med Chem (1998)
In plain English: Repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain.
Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. · J Pharmacol Exp Ther (2009)
In plain English: Anamorelin and ipamorelin administered i.p. had beneficial effects in alleviating cisplatin-induced weight loss during delayed phase.
Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. · Physiol Behav (2024)
In plain English: Ipamorelin is a synthetic peptide with GH releasing properties. We wished to study the metabolic effects of Ipamorelin and GH on selected hepatic measures of alpha-amino-nitrogen conversion during steroid-induced catabolism.
Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H. · Growth Horm IGF Res (2009)
In plain English: These data suggest that, at least in the young female rat, the GHS Ipamorelin is able to exert a dynamic control effect on the somatotroph population and on GH hormone content.
Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. · Histol Histopathol (2002)
In plain English: The acute response to either IPA or growth hormone releasing hormone (GHRH) in terms of plasma GH was not changed [by methylprednisolone].
Malmlöf K, Johansen PB, Haahr PM, Wilken M, Oxlund H. · Growth Horm IGF Res (1999)
In plain English: Ipamorelin (0.014 µmol/kg intravenous) resulted in a significant acceleration of gastric emptying ... through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.
Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. · J Exp Pharmacol (2012)
In plain English: They were designed specifically for their ability to stimulate growth hormone release and may serve as performance enhancing drugs.
Timms M, Hall N, Levina V, Vine J, Steel R. · Drug Test Anal (2014)